News

Commission funds Mutabilis project
Enlarge image

FundingFranceEU

Commission funds Mutabilis project

19.09.2012 - Mutabilis has received €4m funding from the European Union under its FP7 programme.

The project, submitted by the French specialist for infectious diseases, is called "HIVINNOV – generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions". Mutabilis, which is the coordinator of the €10.8m project, formed the consortium in July 2011 comprising eleven research institutions from across Europe. "The Commission was apparently very impressed with the major advances we have made with the compounds we are developing, as well as the quality of the consortium and the research projects proposed," said the scientific director of Mutabilis, Dr. Richard Benarous.

Mutabilis was founded in 2001 to develop new antibiotic treatments.  The French company raised €11.8m in two financing rounds in 2002 and 2004. Mutabilis runs different collaborations, amongst others with German drug developer 4SC. In 2009 FAB Pharmaceuticals SAS acquired Mutabilis lead compound Fab-001, which is a marrow- spectrum antibiotic targeting the fatty acid biosynthesis in S. aureus. Since 2010, the company has been an affiliate of Pharma Omnium International.

The European Union's seventh framework program (FP7), which has been allotted a total budget of €50.5bn for the 2007-2013 period, brings together all the EU's research initiatives under one roof and plays an important role in achieving its growth, competitiveness and employment targets. A budget of €6.05 billion has been assigned to cooperation in human health.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-03/commission-funds-mutabilis-project.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SCANCELL HOLDINGS (UK)29.25 GBP7.93%
  • CELLECTIS (F)32.30 EUR7.31%
  • ALMIRALL (E)17.87 EUR7.26%

FLOP

  • TRANSGENE (F)3.99 EUR-14.56%
  • BAVARIAN NORDIC (D)39.72 EUR-5.61%
  • EUROFINS SCIENTIFIC (F)255.00 EUR-5.39%

TOP

  • PROTHENA PLC (IE)52.67 USD31.8%
  • VERONA PHARMA (UK)5.20 GBP22.4%
  • DBV Technologies (F)51.87 EUR21.8%

FLOP

  • OREXO (S)68.00 SEK-24.7%
  • NORDIC NANOVECTOR (N)26.90 NOK-23.6%
  • SCANCELL HOLDINGS (UK)29.25 GBP-23.5%

TOP

  • ADOCIA (F)67.19 EUR387.9%
  • 4SC (D)4.52 EUR352.0%
  • WILEX (D)3.64 EUR343.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.60 SEK-70.3%
  • NEOVACS (F)1.12 EUR-67.0%

No liability assumed, Date: 30.06.2015